B7-H3 and B7-H1 expression in cerebral spinal fluid and tumor tissue correlates with the malignancy grade of glioma patients

Baral,Aparajita; Ye,Hong  Xing; Jiang,Pu  Cha; Yao,Yu; Mao,Ying

doi:10.3892/ol.2014.2268

B7-H3 and B7-H1 expression in cerebral spinal fluid and tumor tissue correlates with the malignancy grade of glioma patients

Authors:
- Aparajita Baral
- Hong Xing Ye
- Pu Cha Jiang
- Yu Yao
- Ying Mao
View Affiliations

Affiliations: Department of Neurosurgery, Zhongnan Hospital, Wuhan University, Wuhan, Hubei 430071, P.R. China, Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China
Published online on: June 19, 2014 https://doi.org/10.3892/ol.2014.2268
Pages: 1195-1201

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The B7 family consists of activating and inhibitory molecules that regulate immune responses. Recent research demonstrated the roles of soluble B7‑H3 (sB7‑H3) and soluble B7‑H1 (sB7‑H1) in the blood serum of various tumors; however, none of these studies investigated the expression of these proteins in the cerebral spinal fluid (CSF) and blood serum of patients with glioma. The aim of the present study was to investigate the expression of B7‑H3 and B7‑H1 in the CSF, blood serum and tissues of patients with glioma and their correlation with clinicopathological data. Between January 2012 and November 2012, samples were obtained from 78 patients with glioma, four CSF samples were obtained from patients with a moderate traumatic brain injury, four brain tissue samples were obtained from patients with a traumatic brain injury and 40 blood serum samples were obtained from healthy individuals. The expression of B7-H3 and B7-H1 in the CSF, blood serum and tumor samples of the patients with high‑grade glioma was found to be higher than that in the patients with low‑grade glioma. However, no significant differences in sB7‑H3 and sB7‑H1 expression were observed in the blood serum of the patients with glioma compared with the healthy control subjects. In addition, the expression of sB7‑H3 and sB7‑H1 in the CSF of the patients with glioma was higher than that in the CSF of the patients with a moderate traumatic brain injury. Furthermore, in the patients with glioma, B7‑H3 and B7‑H1 expression in the CSF and tumor tissue, although not in the blood serum, correlated with the glioma grade.

View Figures

View References

1	Chapoval AI, Ni J, Lau JS, et al: B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol. 2:2692001.
2	Dong H, Strome SE, Salomao DR, et al: Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 8:793–800. 2002.
3	Hashiguchi M, Kobori H, Ritprajak P, Kamimura Y, Kozono H and Azuma M: Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses. Proc Natl Acad Sci USA. 105:10495–10500. 2008.
4	Zhang G, Hou J, Shi J, Yu G, Lu B and Zhang X: Soluble CD276 (B7-H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum. Immunology. 123:538–546. 2008.
5	Sun J, Chen LJ, Zhang GB, et al: Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma. Cancer Immunol Immunother. 59:1163–1171. 2010.
6	Merimsky O, Shoenfeld Y, Chaitchik S, Yecheskel G and Fishman P: Antigens and antibodies in malignant melanoma. Tumor Biol. 15:188–202. 1994.
7	Streit M and Detmar M: Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene. 22:3172–3179. 2003.
8	Miller AJ and Mihm MC Jr: Melanoma. N Engl J Med. 355:51–65. 2006.
9	Chen YW, Tekle C and Fodstad O: The immunoregulatory protein human B7H3 is a tumor-associated antigen that regulates tumor cell migration and invasion. Curr Cancer Drug Targets. 8:404–413. 2008.
10	Zang X, Sullivan PS, Soslow RA, et al: Tumor associated endothel expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol. 23:1104–1112. 2010.
11	Sun Y, Wang Y, Zhao J, et al: B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer. 53:143–151. 2006.
12	Wu CP, Jiang JT, Tan M, et al: Relationship between co-stimulatory molecule B7-H3 expression and gastric carcinoma histology and prognosis. World J Gastroenterol. 12:457–459. 2006.
13	Roth TJ, Sheinin Y, Lohse CM, et al: B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res. 67:7893–7900. 2007.
14	Yamato I, Sho M, Nomi T, et al: Clinical importance of B7-H3 expression in human pancreatic cancer. Br J Cancer. 101:1709–1716. 2009.
15	Loos M, Hedderich DM, Ottenhausen M, et al: Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer. 9:4632009.
16	Lemke D, Pfenning PN, Sahm F, et al: Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma mediating immune escape and invasiveness. Clin Cancer Res. 18:105–117. 2012.
17	Suh WK, Gajewska BU, Okada H, et al: The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol. 4:899–906. 2003.
18	Luo L, Chapoval AI, Flies DB, et al: B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8⁺ cytolytic T cells. J Immunol. 173:5445–5450. 2004.
19	Ma L, Luo L, Qiao H, et al: Complete eradication of hepatocellular carcinomas by combined vasostatin gene therapy and B7H3-mediated immunotherapy. J Hepatol. 46:98–106. 2007.
20	Geng L, Huang D, Liu J, et al: B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression. J Cancer Res Clin Oncol. 134:1021–1027. 2008.
21	Loos M, Giese NA, Kleeff J, et al: Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer. Cancer Lett. 268:98–109. 2008.
22	Boorjian SA, Sheinin Y, Crispen PL, et al: T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res. 14:4800–4808. 2008.
23	Frigola X, Inman BA, Lohse CM, et al: Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin Cancer Res. 17:1915–1923. 2011.
24	Rubin LL and Staddon JM: The cell biology of the blood-brain barrier. Annu Rev Neurosci. 22:11–28. 1999.
25	Tseng SY, Otsuji M, Gorski K, et al: B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med. 193:839–846. 2001.
26	Latchman Y, Wood CR, Chernova T, et al: PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2:261–268. 2001.
27	Yao Y, Tao R, Wang X, Wang Y, Mao Y and Zhou LF: B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells. Neuro Oncol. 11:757–766. 2009.
28	Chen X, Zhang G, Li Y, et al: Circulating B7-H3(CD276) elevations in cerebrospinal fluid and plasma of children with bacterial meningitis. J Mol Neurosci. 37:86–94. 2009.